Actually, increasing attention to the KEAP1 gene in lung cancer is mainly due to point mutations that show great translational impact in terms of increased risk of cancer progression, shorter overall survival and response of NSCLC patients’ to chemo and biological treatments [3,4,5,31]. The gene discussed is KEAP1; the disease is lung cancer.